Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Women’s healthcare investments are hot. So where are the new menopause drugs?

NK3 receptor antagonists offer a new option, but experts say more are needed.

By Kelly Bilodeau • July 5, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Transgender patients are rarely included in clinical trials. Can pharma fix it?

Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.

By Karissa Waddick • June 29, 2023

Major clinical trial trends transforming life sciences research

From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.

By Karissa Waddick • June 29, 2023

Pharma is still figuring out how to make DEI work. Here are some of the strategies companies are trying

Although DEI efforts have ramped up, the industry is still searching for proven ways to get results.

By Alexandra Pecci • June 28, 2023

A unique study on COVID shows how machine learning can help personalize medicine

Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.

By Kelly Bilodeau • June 26, 2023

DIA’s chief exec is on a mission to grow its footprint across healthcare

Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.

By Michael Gibney • June 22, 2023

Woman of the Week: Stealth BioTherapeutics’ Reenie McCarthy

How the CEO navigated a regulatory odyssey to bring the company’s lead program for an ultra-rare disease to a fast track approval.

By Taren Grom • June 21, 2023

AI has secured a footing in drug discovery. Where does it go from here?

The AI revolution is bringing a new era of drug discovery, and the potential for more uses is greater and faster than ever before.

By Michael Gibney • June 20, 2023

Woman of the Week: Gamida Cell’s Abbey Jenkins

The first-time CEO discusses the lessons she has learned since taking the role last year and how she’s pivoting the company into a commercial entity.

By Taren Grom • June 14, 2023

Zai Lab looks to expand beyond China and make a global impact in oncology

Focused on making a “transformational” impact, the company is developing targeted treatments driven by specific cancer mutations.

By Kelly Bilodeau • June 12, 2023

Is America ready for a new kind of opioid?

Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction. 

By Alexandra Pecci • June 12, 2023

Why cancer could be the ideal realm for psychedelic treatments

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”

By Meagan Parrish • June 9, 2023

Ranking reveals biopharma’s most innovative companies

IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.

By Taren Grom • June 7, 2023

Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

A partnership going on six years between the pharma giant and the Chinese biotech is showing that their CAR-T cell therapy for multiple myeloma is highly effective.

By Michael Gibney • June 5, 2023

A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking

Healthcare pros share the market drivers they believe are having the biggest impact on the industry.

By Taren Grom • June 2, 2023

Woman of the Week: Mirati Therapeutics’ Laurie Stelzer

With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial organization.

By Taren Grom • May 31, 2023

CVS is exiting clinical trials. Does this spell trouble for retail-based research?

Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.

By Kelly Bilodeau • May 30, 2023

Woman of the Week: Cognition Therapeutics’ Lisa Ricciardi

As CEO of the neurogenerative company, Ricciardi is applying her decades of “human capital” to advance Alzheimer’s and dementia treatments.

By Taren Grom • May 24, 2023

The cell ‘atlasing’ approach pushing the limits of drug discovery

Vizgen’s CEO discusses the potential of spatial genomics in the life sciences and the company’s role in the movement.

By Taren Grom • May 24, 2023

The power of genetics — how research into gene sequencing could revolutionize biopharma

Ancient DNA from a deer tooth. A new way to connect genes with disease. Biological super-computing. These genetic advances could play a part in our biopharma future.

By Michael Gibney • May 23, 2023

Biotechs blast experiments into space

Conducting life sciences research in space’s microgravity could have far-ranging implications for drug development on Earth.

By Alexandra Pecci • May 23, 2023

Amid surging Duchenne market, Capricor touts potential ‘backbone’ therapy of the space

The company's CEO on the vital role its late-stage candidate could play in the lives of DMD patients. 

By Kelly Bilodeau • May 22, 2023

Biden’s pick to lead the NIH faces an uphill battle

Pending Senate confirmation, NCI head Monica Bertagnolli will take the helm of the collection of research organizations as it faces increasing bipartisan scrutiny. 

By Karissa Waddick • May 18, 2023

What pharma can teach biotech about the life cycle management of a drug

Global product teams are common in pharma but have yet to gain traction in biotech. Here's why this model can work.

By Dr. Stephen Dale and Kathleen Ford • May 18, 2023